8-K: Rallybio Corporation Faces Nasdaq Delisting Threat Due to Low Share Price

Rallybio Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, putting its listing at risk.

Summary

• Rallybio Corporation received a notification from Nasdaq on February 24, 2025, stating that its common stock price has fallen below the required $1.00 per share for 30 consecutive business days.
• This violates Nasdaq Listing Rule 5450(a)(1).
• Rallybio has until August 25, 2025, to regain compliance by maintaining a share price of at least $1.00 for a minimum of 10 consecutive business days.
• The company intends to monitor its stock price and explore options to regain compliance.
• If compliance isn't achieved, Rallybio may apply to transfer its listing to the Nasdaq Capital Market for an additional 180-day compliance period, provided it meets other listing requirements.
• Failure to regain compliance or transfer to the Nasdaq Capital Market could result in delisting, which the company could appeal.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating potential financial distress and uncertainty about the company's future.

Positives

• The notification has no immediate impact on the listing of Rallybio's common stock.
• Rallybio has a period of 180 days to regain compliance.
• The company may be eligible for an additional 180-day period to regain compliance if it applies to transfer the listing of its common stock to the Nasdaq Capital Market.
• Rallybio has the option to appeal a delisting determination.

Negatives

• Rallybio's stock price has fallen below the minimum bid price of $1.00 per share for 30 consecutive business days.
• The company is at risk of being delisted from the Nasdaq Global Select Market if it fails to regain compliance.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• Transferring to the Nasdaq Capital Market requires meeting other listing standards.
• Delisting could negatively impact investor confidence and the company's ability to raise capital.

Future Outlook

Rallybio intends to monitor its stock price and explore available options to regain compliance with Nasdaq's listing requirements.

Management Comments

• The Company intends to monitor the closing bid price for its common stock and explore available options to regain compliance within the prescribed time period.

Industry Context

Delisting notices are not uncommon, especially for smaller biotech companies facing challenges in drug development or market conditions. Other companies in similar situations may explore reverse stock splits, capital raises, or strategic alternatives to regain compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have faced similar listing compliance issues in the past.
• Strategies for regaining compliance often include reverse stock splits, which can artificially inflate the share price but may not address underlying business issues.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment.
• Employees may face uncertainty about their job security.
• The company's ability to raise capital may be negatively impacted.

Next Steps

• Rallybio will monitor its stock price.
• Rallybio will explore options to regain compliance with Nasdaq listing requirements.
• Rallybio may apply to transfer its listing to the Nasdaq Capital Market.

Key Dates